Zhonghua yi xue za zhi最新文献

{"title":"[Chinese guideline for the laboratory diagnosis of venous thromboembolism (2026 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20260507-01214","DOIUrl":"10.3760/cma.j.cn112137-20260507-01214","url":null,"abstract":"<p><p>Venous thromboembolism (VTE) is a multifactorial disease induced by the interplay between environmental exposures and genetic predisposition. It features intricate pathological mechanisms and an insidious clinical course, with severe cases potentially resulting in disability or death. In recent years, laboratory assays for VTE have become increasingly diverse,nevertheless, prominent challenges persist, including ambiguous indications for clinical application, inconsistent interpretation criteria, and insufficient evidence-based support. To further promote the standardization of laboratory diagnosis for VTE in China, enhance the safety and efficacy of clinical applications, and ensure the rational utilization of diagnostic resources, initiated by Expert Committee of the National Capacity Building Project for Pulmonary Embolism and Deep Venous Thrombosis Prevention and Treatment, National Health Commission Capacity Building and Continuing Education Center and National Center for Clinical Laboratories, the <i>Chinese guideline for the laboratory diagnosis of venous thromboembolism</i> (<i>2026 edition</i>) was developed in accordance with the methodologies and procedures in the <i>Guiding Principles for the Formulation and Revision of Clinical Practice Guidelines in China (2022 Edition)</i>, the Appraisal of Guidelines for Research and Evaluation Ⅱ (AGREEⅡ), and the Reporting Items for Practice Guidelines in Healthcare (RIGHT). This guideline addresses 12 clinical questions and includes 33 recommendations, covering exclusion diagnosis, etiological analysis, risk assessment and anticoagulation monitoring of VTE. It is intended to establish a VTE laboratory testing system adapted to domestic conditions in China, so as to promote standardization and homogenization of VTE laboratory diagnosis.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 37","pages":"3956-3994"},"PeriodicalIF":0.0,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Stratified and graded diagnosis and treatment strategies for patients with primary aldosteronism].","authors":"X J Wang, X P Cao","doi":"10.3760/cma.j.cn112137-20250416-01034","DOIUrl":"10.3760/cma.j.cn112137-20250416-01034","url":null,"abstract":"<p><p>Primary aldosteronism (PA) is the most common endocrine cause of secondary hypertension and carries a greater risk of cardiorenal complications than essential hypertension. Recent domestic and international guidelines and consensus statements have proposed screening all patients with hypertension for PA. To cope with the massive patient base resulting from universal screening, this article explores practical schemes for the stratified and graded diagnosis and treatment of PA. By employing \"non-drug withdrawal\" and \"minimal-drug withdrawal\" testing protocols, PA screening can be feasibly implemented in primary care settings. Based on simple clinical parameters-including serum potassium, plasma aldosterone levels, and blood pressure-patients are stratified into mild, moderate, and severe categories, along with an estimated probability of unilateral PA. Patients with mild disease, unwilling to undergo surgery, or those who are not surgical candidates can receive medical therapy and follow-up directly at primary care facilities. For moderate-to-severe patients who are willing and eligible for surgery, referral to higher-level hospitals with specialized expertise is indicated, where confirmatory aldosterone suppression testing and adrenal venous sampling are performed for subtype classification. Unilateral disease is treated with surgical resection of the affected adrenal gland, whereas bilateral disease is managed medically. This approach enables timely and appropriate diagnosis and treatment of PA across a broader range of healthcare institutions, fulfilling the paradigm of \"universal screening-stratified management-individualized therapy\".</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 37","pages":"3934-3938"},"PeriodicalIF":0.0,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on the clinical application of continuous glucose monitoring in critically ill patients (2026 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20260616-01560","DOIUrl":"10.3760/cma.j.cn112137-20260616-01560","url":null,"abstract":"<p><p>Glycemic fluctuations are highly prevalent among critically ill patients. Glycemic abnormalities constitute an independent risk factor for adverse outcomes, and their effective identification and management are essential to improving clinical prognosis in this population. Continuous glucose monitoring (CGM) technology, which continuously and in real time captures interstitial fluid glucose concentrations, provides multidimensional glycemic metrics and offers a novel technical approach to overcoming the inherent limitations of conventional intermittent glucose monitoring, thereby enabling refined glycemic management in critically ill patients. However, systematic guidance for its standardized application in the intensive care units (ICU) setting remains lacking. To address this gap, the Branch of Critical Care Medicine, China Association for Disaster and Emergency Rescue Medicine, convened a multidisciplinary panel of experts in critical care medicine, endocrinology, and nursing. Drawing on international evidence-based literature and clinical practice issues specific to China, the panel jointly developed the present consensus, with the aim of providing guidance for the standardized and individualized application of CGM in adult ICU patients. This consensus puts forward 27 recommendations addressing 12 questions regarding the use of CGM in critically ill patients. The content covers the definition, classification and hazards of glycemic abnormalities in critically ill patients, common blood glucose monitoring methods and their clinical implications, eligible populations for CGM, data interpretation, quality control and routine care of CGM, as well as accessibility and economic costs.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 37","pages":"3995-4008"},"PeriodicalIF":0.0,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149149603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on the clinical application of continuous glucose monitoring in adult patients during the perioperative period (2026 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20260411-00984","DOIUrl":"10.3760/cma.j.cn112137-20260411-00984","url":null,"abstract":"<p><p>Perioperative glycemic abnormalities, including hyperglycemia, hypoglycemia, and glycemic variability, are important determinants of postoperative outcomes. Conventional glucose monitoring has inherent temporal limitations and fails to capture dynamic glycemic fluctuations in a timely manner. Continuous glucose monitoring (CGM) enables real-time, continuous assessment of glucose levels and trends, thereby facilitating more precise glycemic management. To standardize its clinical application, the Chinese Society of Anesthesiology, in collaboration with the National Alliance of Geriatric Anesthesia, convened a multidisciplinary expert panel to develop the \"Expert consensus on the clinical application of CGM in adult patients during the perioperative period (2026 edition)\". Key clinical issues, including monitoring strategies across different perioperative phases, data interpretation, and management of special populations, were systematically reviewed and deliberated by the expert panel, resulting in 20 recommendations. This consensus applies primarily to adults with diabetes scheduled to undergo surgery and adults at high risk of perioperative glycemic variability. It covers risk assessment for perioperative dysglycemia, interpretation of CGM data, preoperative initiation and assessment, and intraoperative monitoring and confirmatory testing. It also addresses postoperative handover and continued management, together with the use of CGM in special populations and specific surgical settings. This consensus aims to guide the standardized perioperative use of CGM, optimize glycemic management and improve patient safety.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 36","pages":"3846-3865"},"PeriodicalIF":0.0,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149031371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Collaborative innovation in devices and methodology propels cardiovascular interventional occlusion into a new era].","authors":"W H Ju, D L Zhuang, Z W Nong, X B Pan","doi":"10.3760/cma.j.cn112137-20260703-01676","DOIUrl":"10.3760/cma.j.cn112137-20260703-01676","url":null,"abstract":"<p><p>The development of cardiovascular interventional therapies has always been closely linked to synergistic innovation in devices, materials, and methodologies. Taking occlusion technique as an example, traditional metal occluders have a fixed shape and are relatively rigid; their inadequate morphological and mechanical adaptation to the dynamic structure of the heart may affect patients' long-term prognosis. This article reviews biodegradable occluders and magnetofluid-based in situ adaptive shaping technique, exploring the progress and challenges in the field of interventional occlusion regarding device design, material systems, and tissue repair concepts, and discusses the methodological value of ultrasound-guided intervention in the translation of novel materials and non-metallic devices. In the future, it will be necessary to deepen our understanding of these topics, strengthen multidisciplinary collaboration and the development of clinical translation platforms, and drive cardiovascular interventional occlusion therapy toward greater precision, lower physiological burden, evidence-based practices, and scalable technologies.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 36","pages":"3815-3819"},"PeriodicalIF":0.0,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149031449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Guideline for the diagnosis, treatment and management of membranous nephropathy (2026 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20260808-01958","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20260808-01958","url":null,"abstract":"<p><p>Membranous nephropathy (MN) is one of the most common primary glomerular diseases in China. In recent years, substantial progress has been made in the diagnosis, treatment, and management of MN both domestically and internationally, and a growing body of new evidence has emerged. Therefore, it is imperative to standardize current diagnostic and therapeutic approaches and to provide clinicians with actionable, evidence-based guidance. The National Clinical Research Center for Kidney Diseases has organized a guideline working group to develop the \"Guideline for the diagnosis, treatment and management of membranous nephropathy (2026 edition)\". This guideline adopts the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to evaluate the quality of evidence and strength of recommendations, with the final recommendations presented as formal \"Recommendations\" and \"Practice Suggestions\". The guideline focuses specifically on the diagnosis, risk stratification, treatment strategies, and comprehensive management of MN, with the aim of providing clinicians with a practical reference tosupport scientific, well-standardized therapeutic decision-making and disease management.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 ","pages":"4081-4120"},"PeriodicalIF":0.0,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149026276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effect and safety of device-preserving revision surgery in patients with device erosion following artificial urinary sphincter and sacral neuromodulation implantation].","authors":"L F Meng, M Wang, S X Wang, J P Wang, H M Hou, Y H Zhou, S Y Zhao, J Y Wu, M Y Du, L Wang, J Wang, J Chen, Y Y Lyu, Y Zhang, Y Zhang, X X Qi, J Wang, X Li, J Y Wang, Y G Zhang","doi":"10.3760/cma.j.cn112137-20251226-03439","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20251226-03439","url":null,"abstract":"<p><p>Seven patients with lower urinary tract dysfunction who developed skin erosion after implant surgery at Beijing Hospital between June 2022 and November 2025 were prospectively studied. Follow-up was conducted at 1 month postoperatively (outpatient visit), and at 3, 6, and 12 months, and annually thereafter via telephone interviews, to assess wound healing, device function (where applicable), and complications. The age was (50.6±25.2) years. Time since implantation [<i>M</i> (<i>Q</i>₁,<i>Q</i>₃)] was 15 (12, 36) months, with erosion duration of 0.50 (0.17, 1.00) months. All patients were Clavien-Dindo grade Ⅲ. Three had artificial urethral sphincter (AUS) erosion: 2 with control pump extrusion underwent device-preserving debridement and revision; 1 developed urethral injury, scrotoperineal abscess, and systemic infection from catheterization with the AUS activated, requiring device removal, partial urethrectomy, and end-to-end anastomosis. Four had sacral neuromodulation (SNM) erosion: three with surgical-site breakdown and pulse generator exposure underwent device-preserving revision; 1 with fluctuance, tenderness, and purulent discharge required SNM explantation. Median follow-up was 14 (1, 23) months. Both AUS-preserved patients recovered uneventfully, with device reactivation at 6 weeks and social continence at last follow-up; the AUS-removed patient returned to pre-implant incontinence levels. All 3 SNM-preserved patients healed well with normal device function; the SNM-explanted patient returned to pre-SNM symptom levels. No surgery-related complications occurred by December 2025. Device-preserving revision is feasible for implant erosion without abscess or systemic infection and with adequate subcutaneous fat, provided risks are thoroughly discussed and informed consent is obtained.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 35","pages":"3798-3802"},"PeriodicalIF":0.0,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Mechanism of ethionine-induced neural tube defects via regulation of the Wnt/β-catenin pathway through the KDM5A/H3K4me3 axis].","authors":"J J Gao, Q Mu, H Zhang, X B Zhang, R Cao, L Zhang, Y Y Guo","doi":"10.3760/cma.j.cn112137-20260422-01090","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20260422-01090","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To explore the molecular mechanisms by which ethionine induces neural tube defects (NTD) through regulating the lysine demethylase 5A (KDM5A)/trimethylated lysine 4 of histone H3 (H3K4me3) axis and modulating the Wnt/β-catenin signaling pathway. &lt;b&gt;Methods:&lt;/b&gt; Specific pathogen-free adult male and female C57BL/6 mice (80 females and 35 males) were housed overnight in a 2∶1 female-to-male ratio. Vaginal plugs were examined the following morning to confirm pregnancy. Pregnant mice were randomly divided into two groups: the ethionine experimental group (ethionine group) and the control group. At embryonic day 7.5 (E7.5), the ethionine group received a single intraperitoneal injection of ethionine (500 mg/kg) to establish the NTD model, while the control group was injected with an equal volume of normal saline, with 21 mice in each group. At E10.5, pregnant mice were sacrificed and embryos were collected for observation and photography under a stereomicroscope. Brain tissues from embryos of both groups were harvested for transcriptome sequencing. The expression levels of KDM5A, H3K4me3, Wnt/β-catenin pathway components [β-catenin, transcription factor 4 (TCF4), axis inhibition protein 2 (Axin2), phosphorylated glycogen synthase kinase 3β (p-GSK3β)], and cell proliferation-related proteins [G1/S-specific cyclin-D1 (Cyclin D1), proliferating cell nuclear antigen (PCNA), Myc oncogene (c-Myc)] were assessed by Western blotting, real-time quantitative polymerase chain reaction (RT-qPCR), and immunofluorescence. An additional KDM5A-specific inhibitor GSK-4J treatment group (GSK-4J group) and ethionine combined with GSK-4J treatment group (ethionine+GSK-4J group) were included to verify the regulatory role of the KDM5A/H3K4me3 axis. The pregnant mice in the GSK-4J group received intraperitoneal injection of GSK-4J (7 mg/kg) and the ethionine+GSK-4J group were injected with both 7 mg/kg GSK-4J and 500 mg/kg ethionine, with 12 mice in each group. Comparisons between the two groups were performed using independent samples t-test, one-way ANOVA was applied to evaluate the overall differences among multiple groups, and Tukey's honestly significant difference test was adopted for pairwise post-hoc comparisons. &lt;b&gt;Results:&lt;/b&gt; The ethionine treated group exhibited 48.79% (121/248) incidence of incomplete brain structure and morphological malformations, while the malformation rate in the control group was 3.73% (10/268), with a statistically significant difference (P&lt;0.001). Compared with the control group, the ethionine group showed elevated KDM5A mRNA and protein levels, accompanied by reduced H3K4me3 modification levels (all P&lt;0.001); protein expression of β-catenin, TCF4, and Axin2 were decreased (P&lt;0.01, P&lt;0.05), whereas p-GSK3β was increased (P&lt;0.01). Following GSK-4J intervention, the expression of β-catenin, TCF4, and Axin2 was partially restored (all P&lt;0.01), and the percentage of Cyclin D1-positive cells, as well as the expression","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 35","pages":"3782-3789"},"PeriodicalIF":0.0,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on the management of traumatic brain injury in mass casualty incidents (2026 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20260624-01605","DOIUrl":"10.3760/cma.j.cn112137-20260624-01605","url":null,"abstract":"<p><p>The management of traumatic brain injury (TBI) in mass casualty incidents (MCI) is characterized by strong time dependence, complex injury patterns, and acute strain of medical resources, rendering it substantially more challenging than routine clinical practice. Currently, most existing domestic and international TBI guidelines and consensus statements are developed for daily medical scenarios, and lack systematic full-process standard tailored to the resource-constrained MCI environment. To fill this gap, the Chinese Neurosurgical Society convened a multidisciplinary expert panel covering neurosurgery, critical care medicine and evidence-based medicine and other disciplines. In strict accordance with international methodological standards for guideline development, the panel systematically searched the literature, completed evidence quality appraisal and subsequently formulated the <i>Expert</i> <i>consensus on the management of traumatic brain injury in mass casualty incidents (2026 edition)</i>. This consensus covers the entire process of TBI care in MCI treatment: general principles and emergency response system, safety and protection of rescue personnel and professional team development, on-site triage and emergency life support, safe transport and tiered triage, in-hospital standardized treatment and priority management, intracranial pressure monitoring and standardized management, in-hospital complication prevention and comprehensive management, and early rehabilitation and psychological support. The panel graded the quality of evidence and strength of recommendations using the Oxford University centre for evidence-based medicine levels of evidence framework (2009) and reached a consensus through Delphi expert consultation, forming in 42 recommendations. Guided by the core principle of \"maximizing treatment outcomes with limited resources\", this consensus defines tiered decision-making rules based on injury severity, clarifies triage priorities for mass casualties, and specifies full-process care protocols. It can provide evidence-based reference and practical basis for medical institutions at all levels and health administrative authorities in China to construct MCI-TBI emergency response systems, standardize clinical practice, and carry out specialized personnel training.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 ","pages":"3724-3745"},"PeriodicalIF":0.0,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148901027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Development history of the Diabetes Foot and Peripheral Vascular Disease Group of the Chinese Medical Association Chinese Diabetes Society: a review and prospect].","authors":"Z R Xu, X X Ran","doi":"10.3760/cma.j.cn112137-20260709-01728","DOIUrl":"10.3760/cma.j.cn112137-20260709-01728","url":null,"abstract":"<p><p>The Diabetic Foot Group of the Chinese Diabetes Society, Chinese Medical Association was founded in 1995 and renamed the Diabetes Foot and Peripheral Vascular Disease Group (hereinafter referred to as the Group) in 2012. Over the past 30 years, through the persistent efforts of successive generations of specialists, the Group has achieved fruitful outcomes in clinical practice, scientific research, talent cultivation, international academic exchanges and other fields. This paper reviews the developmental course of the Group, summarizes the work accomplished by its seven successive committees, analyzes the gaps between domestic research on diabetic foot and peripheral vascular diseases in China and the advanced international standards, and puts forward proposals for the future development of the Group.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 35","pages":"3665-3673"},"PeriodicalIF":0.0,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}